Navigation Links
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Date:4/2/2008

ent to production and sale of vaccines.

One goal is to complete the registration of IMVAMUNE(R). The vaccine will then be commercialized via sales to the United States and other countries.

In addition, the intention is to build up a biodefense portfolio of projects that can complement IMVAMUNE(R) and ensure the Company a sustained and growing business.

As part of building up this portfolio, Bavarian Nordic has initiated a preclinical program for an anthrax vaccine. The Company sees a number of synergies - both in the development and in market approach which support the development of such a vaccine. Also, it is expected that a combined anthrax and smallpox vaccine can be developed and thus Bavarian Nordic would be able to offer one vaccine against two of the top biological threats. The anthrax program is expected to enter Phase I in 2008.

Cancer

In the short term, the goal is to complete the Phase I/II studies of the vaccine candidate for breast cancer and to initiate Phase I/II studies of the vaccine candidate for prostate cancer.

As and when positive clinical data are obtained, partnering of the projects will be considered and the Company will also keep an eye on potential in-licensing opportunities.

The cancer business area has been given a higher priority and it is the Company's goal to expand the cancer portfolio. Later in 2008 the Company expects to announce initiatives to strengthen this area.

Infectious diseases

The Company has a number of projects in infectious diseases, all of which are at an early development stage: HIV, measles and RSV, dengue fever and Japanese encephalitis. The goal with the first two projects is to complete early-stage clinical trials. If supported by the data obtained, the option of placing these projects in external partnerships will be explored. Alternatively, the Company will seek other external funding. For the latter two projects, discussions with a potential externa
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
9. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... presentations at three investor conferences: , Wednesday, September ... in New York at the New ... PM at the BioCentury NewsMakers Conference in New ... Center , Thursday, September 17 at 9:30 AM at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... regulatory compliance, quality systems, analytical testing, education and consulting services for the ... in medical device products/processes development, design control, validation, quality assurance and regulatory ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... on technologies and applications. The report starts with ... estimation of markets. Technologies include array comparative genomic ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3
... 12 WaferGen Biosystems,Inc. (OTC Bulletin Board: ... genotyping, cell biology and stem cell research ... demonstrated the,performance of the company,s SmartChip(TM) Real-Time ... platform,s ongoing alpha testing program. Initial ...
... NANJING, China, Jan. 12 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... and supplier of branded generic,pharmaceuticals and manufacturer of ... Endostar) in China, today announced preliminary revenue,and earnings ... Based upon preliminary data for ...
... Jan. 9 Houlihan Smith & Co., Inc.,acted ... equity investment,into Sottera, Inc. d/b/a NJOY, as announced ... of Houlihan Smith & Company, Inc. The,transaction ... McGaugh.,Terms were not disclosed. , ...
Cached Biology Technology:WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... on identifying which patients were likely to have poor ... measuring how a certain non-toxic dye was eliminated by ... of liver function, and therefore a reliable indicator of ... simple non-invasive device to measure the dye, making it ...
... top of the marine food chain, albatrosses accumulate toxic ... bodies. A new study has found dramatic differences in ... forage in different areas of the North Pacific. Researchers ... increased in both species over the past ten years. ...
... humans began scrubbing off and discarding the outer layer ... Now, for the first time, scientists in Japan have ... rice bran, significantly lowers blood pressure in rats whose ... their findings in the March 8 issue of the ...
Cached Biology News:Predicting successful outcomes in living-donor liver transplants 2Predicting successful outcomes in living-donor liver transplants 3Albatross study shows regional differences in ocean contamination 2Albatross study shows regional differences in ocean contamination 3How nice, brown rice: Study shows rice bran lowers blood pressure in rats 2
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Red Standard is sodium salt of resorufin....
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: